Cocrystal Pharma Announces Dosing Complete in Phase 1b Norovirus Study

What Happened
Cocrystal Pharma, Inc. (COCP) filed a Form 8-K on September 9, 2026 (Regulation FD Disclosure) to announce that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139). The study is evaluating CDI-988 as both a preventive and a treatment for norovirus infections. The company furnished a press release dated September 9, 2026 as Exhibit 99.1.

Key Details

• Last subject dosed in the Phase 1b norovirus challenge study (ClinicalTrials.gov identifier NCT07198139).
• Investigational drug: CDI-988 being tested for both prevention and treatment of norovirus.
• Disclosure made via press release dated September 9, 2026; press release furnished as Exhibit 99.1 to the 8-K.
• Filing type: Form 8-K, Item 7.01 (Regulation FD Disclosure).

Why It Matters
Completing dosing in a Phase 1b challenge study is a development milestone — it advances CDI-988 through early human testing and moves the program closer to potential safety and efficacy data readouts. For investors, this is a nonfinancial operational update signaling progress in Cocrystal’s clinical pipeline; it does not by itself provide efficacy or regulatory outcomes. Further updates or data releases will be needed to assess clinical results and any potential impact on the company’s valuation.